Owners, management and financials
CVR: 44420449
EUR 34,912,000
Gross profit
Net result: EUR 892,000
ASCENDIS PHARMA A/S (100%)
CVR · view owners
Henrik Bolgan Thomsen
Board: Michael Wolff Jensen (chair) and 2 members
CVR · view management
Active
Founded 6 November 2023
CVR · view overview
0 employees
Annual report 2025 · average
Director role ended: Camilla Andrea Harder Hartvig
CVR · 04/02/2025
View the full event history
Ascendis Pharma Europe A/S is a Danish company of the type Aktieselskab based in Hellerup, founded in 2023. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The management consists of Henrik Bolgan Thomsen. The board consists of Michael Wolff Jensen (chair), Anni Lotte Kirstine Pedersen and Jan Møller Mikkelsen. The company is owned by ASCENDIS PHARMA A/S. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of EUR 34,912,000 and a net result of EUR 892,000. Equity in the 2025 report amounted to EUR 940,000.
Selskabets formål er at drive virksomhed ved marketing, salg og distribution af farmaceutiske produkter og relaterede aktiviteter samt at eje andele af virksomheder med lignende formål.
Source: annual reports filed with the Danish Business Authority.
| Period | Gross Profit | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/01/2025 – 31/12/2025 | 34.9 mio. EUR | 892 t. EUR | 34 mio. EUR | 940 t. EUR | 0 |
Compared to 404 companies in Engroshandel med medicinalvarer og sygeplejeartikler
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningThe CVR number of Ascendis Pharma Europe A/S is 44420449.
Ascendis Pharma Europe A/S is owned by ASCENDIS PHARMA A/S.
The management of Ascendis Pharma Europe A/S consists of Henrik Bolgan Thomsen.
The board of Ascendis Pharma Europe A/S consists of Michael Wolff Jensen, Anni Lotte Kirstine Pedersen and Jan Møller Mikkelsen, with Michael Wolff Jensen as chair.
In 2025, Ascendis Pharma Europe A/S reported a gross profit of EUR 34,912,000.
Ascendis Pharma Europe A/S had an average of 0 employees in the 2025 financial year according to the annual report.
Claim this page to add your logo and social links. Free to get started.
Ascendis Pharma Europe A/S has published its annual report for 2025. Gross profit came to DKK 34,912,000, and the net result was DKK 892,000.
Ascendis Pharma Europe A/S has published its interim report for the period November 6, 2023 – December 31, 2024.
As of February 4, 2025, Camilla Andrea Harder Hartvig has stepped down as adm. dir. of Ascendis Pharma Europe A/S.
As of October 29, 2024, Henrik Bolgan Thomsen is registered as director of Ascendis Pharma Europe A/S.
As of November 6, 2023, DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of Ascendis Pharma Europe A/S.
As of November 6, 2023, Michael Wolff Jensen has joined the board of directors of Ascendis Pharma Europe A/S.
As of November 6, 2023, Jan Møller Mikkelsen has joined the board of directors of Ascendis Pharma Europe A/S.
As of November 6, 2023, Anni Lotte Kirstine Pedersen has joined the board of directors of Ascendis Pharma Europe A/S.
As of November 6, 2023, Camilla Andrea Harder Hartvig is registered as adm. dir. of Ascendis Pharma Europe A/S.
As of November 6, 2023, ASCENDIS PHARMA A/S is registered as an owner of Ascendis Pharma Europe A/S with an ownership share of 100%.
Ascendis Pharma Europe A/S was founded on November 6, 2023.
Companies in the same industry and area
CVR 25361695
CVR 41344806
CVR 39870665
CVR 37231304
CVR 46354729
